Objective: This phase 3, laboratory classroom study assessed the efficacy and safety of
methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared …

Objective: To examine methylphenidate extended-release chewable tablets (MPH ERCT)
dose patterns, attention-deficit/hyperactivity disorder (ADHD) symptom scores, and safety …

Objective: The aim of this study was to compare efficacy and safety of two long-acting
formulations of methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD) in …

Objective: The purpose of this study was to assess the time of onset and time course of
efficacy over 12.0 hours of extended-release multilayer bead formulation of methylphenidate …

Objectives: To assess the efficacy and safety of a methylphenidate hydrochloride extended-
release capsule (MPH-MLR) formulation in treating attention-deficit/hyperactivity disorder …

Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer,
extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the …

Objective: The purpose of this study was to determine the efficacy of NWP06, a novel
extended-release (ER) liquid formulation of methylphenidate (MPH), compared with placebo …

Objective. To compare the efficacy, safety, and tolerability of once-daily administration of
modified-release methylphenidate (MPH MR) with placebo in children with attention …

Objective: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODTs)
represent a new technology for MPH delivery. ODTs disintegrate in the mouth without water …

Objectives: To study the safety and efficacy of the long-acting methylphenidate formulation
PRC-063 in adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods …